Spero's Scientific Exchange

Posters and Publications

Filter all Publications & Posters

Download a complete bibliography from each of our ongoing investigational programs below.

Filters
Tebipenem HBr
SPR720
SPR206
SPR741

Tebipenem HBR

Clinical
Microbiology

Clinical and microbiological outcomes for Enterobacterales uropathogens in the Phase 3 ADAPT-PO Study of oral tebipenem pivoxil hydrobromide

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR206

Clinical
PK/PD

SPR206 Pharmacokinetics (PK) in Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Adult Subjects

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

HEOR

Enterobacterales Resistance Patterns for Extended Spectrum β lactamase (ESBL) Positive and Multidrug Resistant (MDR) Urine Isolates Collected and Tested from 295 Outpatient US Facilities in 2019

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Effectiveness of TBP PI HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT PO

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

HEOR

The Economic Burden of Adverse Events Requiring Acute Care Service from Outpatient Parenteral Antibiotic Treatment (OPAT)

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study. BMC Infect Dis. 2021 Feb 8;21(1):159.

2021
HEOR
ARCHIVE
View Full Text Link
Open Resource

SPR206

No items found.

Zabawa TP, Pucci MJ, Parr TR Jr, Lister T. Treatment of Gram-negative bacterial infections by potentiation of antibiotics. Curr Opin Microbiol. 2016 Oct;33:7-12. 

2016
Reviews
ARCHIVE
View Full Text Link
Open Resource

SPR741

Microbiology

Zurawski DV, Reinhart AA, Alamneh YA, et al. SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01239-17.

2017
Non-Clinical
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Antimicrobial Susceptibility and Cross-Resistance Patterns among Common Complicated Urinary Tract Infections in U.S. Hospitals, 2013 to 2018. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00346-20. 

2020
HEOR
ARCHIVE
View Full Text Link
Open Resource

SPR206

Non-Clinical

Understanding the SAR interplay for kidney exposure and cytotoxicity facilitates the design of improved polymyxin derivatives – identification of SPR206 as a development candidate

2018
ASM/ESCMID
ARCHIVE
View Full Text Link
Open Resource

SPR720

Microbiology
Non-Clinical

Treatment of Mycobacterium avium subspecies hominissuis (MAH) infection with a novel gyrase inhibitor (SPR719/SPR720) was associated with a significant decrease in bacterial load as assessed in macrophages, biofilm and in mice

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Tebipenem: An oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US medical centers during 2019

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology

The impact of varied test conditions on the in vitro activity of SPR206, a next-generation polymyxin B analog, against drug-susceptible and multidrug-resistant gram-negative pathogens

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

No items found.

Thomas J, Navre M, Rubio A, Coukell A. Shared Platform for Antibiotic Research and Knowledge: A Collaborative Tool to SPARK Antibiotic Discovery. ACS Infect Dis. 2018 Nov 9;4(11):1536-1539. 

2018
Reviews
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

The impact of antibiotic resistance on hospitalized patients with Enterobacteriaceae (ENT) urinary tract infections (UTI): a multicenter analysis

2018
ASM/ESCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

The 30-day economic burden of newly diagnosed complicated urinary tract infections in Medicare patients.

2022
ISPOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

The burden of resistance among urinary tract isolates of Escherichia coli in the United States in 2017

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Lodise T, Nowak M, Rodriguez M. The 30-Day Economic Burden of Newly Diagnosed Complicated Urinary Tract Infections in Medicare Fee-for-Service Patients Who Resided in the Community. Antibiotics 2022; 11(5):578.

2022
HEOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Tebipenem pivoxil hydrobromide: Safety and tolerability profile of the first oral carbapenem for complicated urinary tract infection and acute pyelonephritis

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Tebipenem in vitro activity against a collection of pathogens responsible for urinary tract infections in the US

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem against clinically significant gram-negative bacteria isolated from patients with cancer

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Tebipenem: An oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US medical centers during 2019

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

PK/PD

Talley AK, Thurston A, Moore G, et al. First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother. 2021 Sep 7:AAC0120821.

2021
Clinical
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Stokes SS, Vemula R, Pucci MJ. Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323-1331.

2020
Reviews
ARCHIVE
View Full Text Link
Open Resource

SPR741

Non-Clinical
Microbiology

SPR741 in combination with minocycline increases antibacterial efficacy in vitro and in vivo against XDR-Acinetobacter baumannii in a pulmonary model of infection

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

SPR741

Clinical

Safety of SPR741, a novel polymyxin potentiator, in healthy adults receiving single- and multiple-dose intravenous administrations

2018
ECCMID
ARCHIVE
View Full Text Link
Open Resource

SPR741

Microbiology

Stainton SM, Abdelraouf K, Utley L, et al. Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00239-18.

2018
Non-Clinical
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Reviews

SPR994: oral carbapenem for the treatment of complicated urinary tract infections

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Patient demographics and comorbidity profiles associated with hospitalized patients admitted with resistant versus susceptible urinary tract infections (UTI): a multicenter analysis

2018
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Reviews

SPR994 (oral carbapenem prodrug): what’s in the pipeline?

2018
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

Reviews

SPR720: novel oral therapy for non-tuberculous Mycobacterial (NTM) infections

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
PK/PD

Single- and multiple-ascending dose (SAD/MAD) study demonstrates the human pharmacokinetics (PK) and tolerability of SPR994 (tebipenem pivoxil hydrobromide), an oral carbapenem (CP), at the predicted therapeutic dose 

2019
ASM/ESCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
PK/PD

Single-and multiple-ascending dose (SAD/MAD) study demonstrates the human pharmacokinetics (PK) and tolerability of SPR994 (tebipenem pivoxil hydrobromide), an oral carbapenem (CP), at the predicted therapeutic dose

2019
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

SPR720

Microbiology
Non-Clinical

SPR720, a novel aminobenzimidazole gyrase inhibitor, demonstrates potent efficacy against Mycobacterium avium ATCC 700898 in a chronic C3HeBFeJ mouse infection model

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

No items found.

Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clin Infect Dis. 2017 Jul 1;65(1):141-146.

2017
Reviews
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Rubio A, Pucci MJ, Jain A. Characterization of SPR994, an orally available carbapenem, with activity comparable to intravenously administered carbapenems. ACS Infect Dis. 2018 Oct 12;4(10):1436-1438. 

2018
Non-Clinical
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Resistance to oral antibiotics among urinary tract infection isolates of Escherichia coli from the United States and Europe in 2017

2019
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR
Microbiology

Relationship between receipt of prior antibiotics and presence of antibiotic resistance among adult outpatients with complicated urinary tract infection

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Pre and post hospitalization resource utilization and costs associated with urinary tract infection (UTI) in both commercial and Medicare populations

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

No items found.

Pucci MJ, Dougherty TJ. Editorial overview: Antimicrobials: fighting bacterial infections in the 21st century-thinking outside of the box. Curr Opin Microbiol. 2016 Oct;33:v-vii

2016
Reviews
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
PK/PD

Plasma pharmacokinetics and intrapulmonary penetration of tebipenem in healthy subjects

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD

Population pharmacokinetic analyses for tebipenem after the administration of tebipenem pivoxil hydrobromide

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

Non-Clinical
Microbiology

Potent activity of a novel gyrase inhibitor (SPR719/SPR720) in vitro and in a prolonged acute Mycobacterium abscessus mouse model of infection

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Pidot SJ, Porter JL, Lister T, Stinear TP. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 2021 Jul 26;15(7):e0009636. 

2021
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD

Phase 3 dose selection for tebipenem

2019
ECCMID
ARCHIVE
View Full Text Link
Open Resource

SPR720

Clinical
PK/PD

Phase 1 first-in-human single-and multiple-ascending dose trial demonstrates pharmacokinetics and tolerability of SPR720, an oral DNA GyrB inhibitor for Mycobacterial infections

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

PK/PD
Non-Clinical
Microbiology

Pharmacokinetics/pharmacodynamics of the novel gyrase inhibitor SPR719/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium complex disease

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Patel G, Rodvold KA, Gupta VK, et al. Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment. Antimicrob Agents Chemother. 2022 Apr 14. doi: 10.1128/aac.02407-21. Epub ahead of print.

2022
PK/PD
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD
Non-Clinical

Pharmacokinetics-pharmacodynamics evaluation of tebipenem pivoxil hydrobromide using the 10-day hollow-fiber in vitro infection model 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD
Microbiology

Pharmacokinetics and pharmacodynamics of tebipenem for multi-drug resistant Enterobacteriaceae

2018
ASM Microbe
ARCHIVE
View Full Text Link
Open Resource
No results found.
There are no results with this criteria. Try changing your search.

Unable to find what you were looking for?  

Download a complete bibliography from each of our ongoing investigational programs below.

Sign up to receive news and announcements.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.